Xcout IntelClover Biopharmaceuticals, Ltd. competitors & alternatives
The 12 closest competitors and alternatives to Clover Biopharmaceuticals, Ltd. among biotech companies — ranked by similarity to what Clover Biopharmaceuticals, Ltd. actually does, not by market-cap band.
Subscribe to see Clover Biopharmaceuticals, Ltd.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Clover Biopharmaceuticals, Ltd. at a glance
Clover Biopharmaceuticals, Ltd. is a biotech company headquartered in Shanghai, China. It is publicly listed (02197) with a market capitalisation of $368.8M. Xcout tracks 11 named people at Clover Biopharmaceuticals, Ltd., including Joshua Liang (Chief Executive Officer, Executive Director).
Clover Biopharmaceuticals, Ltd. leadership
- Joshua LiangChief Executive Officer, Executive Director
- Dr. Nicholas JacksonPresident of Global R&D and Alliances
- Peng Liang, Ph.D.Founder, Chief Scientific Officer, Chairman of the Board
- Nicolas Burdin, Ph.D.Global Head of R&D
- Wei Tan, Ph.D.Head of China Research
- Donna Ambrosino, M.D.Non-executive Director
5 more named people on record for Clover Biopharmaceuticals, Ltd., with roles, board committees and tenure — see the full roster →
Top 12 Clover Biopharmaceuticals, Ltd. competitors
Ranked by semantic similarity — how close each company is to Clover Biopharmaceuticals, Ltd. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation. This compound is intended for patients suffering from chronic phase chronic myeloid leukemia that has become resistant to tyrosine kinase inhibitors. Beyond HQP1351, the company boasts a robust pipeline. This includes APG-2575 (Pelcitoclax), an orally administered, selective Bcl-2 inhibitor undergoing Phase Ib/II clinical studies for hematologic and solid tumors; APG-115 (Alrizomadlin), an oral small molecule designed to inhibit the MDM2-p53 protein-protein interaction for various solid and hematological malignancies; and APG-1387 (Nevadotinib), a small molecule inhibitor of apoptosis proteins targeting advanced solid tumors and chronic HBV infections. Further advancing its portfolio, Ascentage is developing APG-1252 (Atoloclab), a small molecule drug aimed at restoring apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins for conditions such as small cell lung cancer (SCLC), lymphoma, and other solid tumors. The pipeline also features APG-2449 (Glecirasib) for non-small-cell lung carcinoma (NSCLC); APG-5918, an orally available and selective EED inhibitor with best-in-class potential in its preclinical phase; APG-265, currently in IND-enabling stages for hematological and solid tumors; and UBX1967/1325, a Phase II candidate targeting the Bcl family for diabetic macular edema (DME). The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical companies, as well as academic institutions. Key partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Established in 2009, Ascentage Pharma is headquartered in Suzhou, China.
Similar biotech company
Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Similar biotech company
Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company further supplies a varicella vaccine; a pneumococcal polysaccharide vaccine designed to prevent Streptococcus pneumoniae infections like pneumonia and septicemia; a quadrivalent influenza vaccine providing defense against two influenza A and two influenza B viruses; and CoronaVac, its vaccine developed to address COVID-19. Additionally, Sinovac's development pipeline features a sabin inactivated polio vaccine, which has concluded Phase III clinical trials for poliomyelitis treatment, alongside a rubella vaccine candidate. The company has established several collaboration agreements, including with GlaxoSmithKline Biologicals SA for the development of measles-containing combination vaccines for the Chinese market; with Tianjin CanSino Biotechnology Inc. to advance a pneumococcal vaccine; and with Instituto Butantan to progress the Phase III clinical trials of CoronaVac, its inactivated COVID-19 vaccine candidate. Sinovac Biotech Ltd. was established in 1993 and maintains its principal offices in Beijing, China.
Biotechnology
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Similar biotech company
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Similar biotech company
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Biotechnology
Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese market. The company's therapeutic candidates encompass a range of modalities, including cutting-edge antibody-drug conjugates (ADCs), oncolytic virus treatments, and diverse immunotherapies. Among its immuno-oncology offerings are HX008 (an anti-PD-1 mAb) and LP002 (an anti-PD-L1 mAb). The ADC portfolio features MRG003 (targeting EGFR), MRG002 (targeting HER2), MRG001 (targeting CD20), MRG004A (targeting TF), and CMG901 (targeting CLDN18.2). Additionally, Lepu Biopharma is advancing the oncolytic virus CG0070, along with various combination therapies such as HX008+OH2, LP002+OH2, and HX008+LP002. Founded in 2018, the company is headquartered in Shanghai, China.
Similar biotech company
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Similar biotech company
SinoMab BioScience Limited is a biopharmaceutical enterprise that specializes in the comprehensive process of discovering, developing, producing, and marketing therapeutic solutions for various immunological disorders. Their approach predominantly involves monoclonal antibody (mAb)-based biologics. A key asset in their portfolio is SM03, an innovative anti-CD22 monoclonal antibody. This drug is currently in Phase III clinical trials for rheumatoid arthritis (RA), with additional clinical investigations underway for other immune-related conditions such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company is also progressing with SN1011, a Bruton's tyrosine kinase inhibitor. This compound is in Phase II clinical trials for pemphigus and has commenced Phase I trials for multiple sclerosis, SLE, and neuromyelitis optica spectrum disorder (NMOSD). Furthermore, SinoMab maintains an active preclinical pipeline. This includes SM17, which targets asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06, intended for RA, SLE, NMOSD, and SS; SM09, in development for NHL and RA; and TNF2, focused on a range of autoimmune diseases. Founded in 2001, SinoMab BioScience Limited is based in Pak Shek Kok, Hong Kong, and conducts its business activities across Mainland China, the Cayman Islands, and Hong Kong.
Similar biotech company
Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.
Similar biotech company
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Similar biotech company
Sinocelltech Group Limited is a Beijing-based biotechnology enterprise. The company's primary focus lies in pioneering and refining the technologies required for both the creation and large-scale production of vital biological agents, specifically recombinant proteins, monoclonal antibodies, and vaccines, throughout China.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Clover Biopharmaceuticals, Ltd. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Clover Biopharmaceuticals, Ltd.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →